News Releases

September 10, 2024
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
September 4, 2024
LakeShore Biopharma Announces Leadership Transitions
August 15, 2024
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
July 5, 2024
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
May 24, 2024
YS Biopharma Announces Name Change to LakeShore Biopharma
May 21, 2024
YS Biopharma Announces Results of Extraordinary General Meeting
May 7, 2024
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
April 29, 2024
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
April 19, 2024
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
April 18, 2024
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Print Page
Email Alerts
RSS Feeds
Contact IR
Site Map Terms of Use Privacy

Contact Info

LakeShore Biopharma, Ltd.

11 Firstfield Road Suite A
Gaithersburg, Maryland 20878 USA

Tel: +1 (212) 537-4035

ir@lakeshorebio.com